Neuroblastoma and treatment-related myelodysplasia/leukemia: The Memorial Sloan-Kettering experience and a literature review

Journal of Clinical Oncology

Volumn 16, Issue 12, 1998, Pages 3880-3889

  Kushner, Brian H ^a   Cheung, Nai Kong V ^a   Kramer, Kim ^a   Heller, Glenn ^a   Jhanwar, Suresh C ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GYRASE INHIBITOR; HYDROXYUREA; IFOSFAMIDE;

CLINICAL ARTICLE; CYTOTOXICITY; FEMALE; FOLLOW UP; HOST SUSCEPTIBILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA; LEUKEMOGENESIS; MALE; MYELODYSPLASIA; NEUROBLASTOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; REMISSION; REVIEW; RISK ASSESSMENT; SCHOOL CHILD;

EID: 0032422239     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.12.3880     Document Type: Review

References (105)

1. Sandler ES, Friedman DJ, Mustafa MM, et al: Treatment of children with epipodophyllotoxin-induced secondary acute myeloid leukemia. Cancer 79:1049-1054, 1997
2. Anderson JE, Gooley TA, Schoch G, et al: Stem cell transplantation for secondary acute myeloid leukemia: Evaluation of transplantation as initial therapy or following induction chemotherapy. Blood 89:2578-2585, 1997
3. Smith MA, Rubinstein L, Cazenave L, et al: Report of the Cancer Therapy Evaluation Program monitoring plan for secondary acute myeloid leukemia following treatment with epipodophyllotoxins. J Natl Cancer Inst 85:554-558, 1993
4. Smith MA, Rubinstein L, Ungerleider RS: Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: Estimating the risks. Med Pediatr Oncol 23:86-98, 1994
5. Felix CA, Hosier MR, Winick NJ, et al: ALL-1 gene rearrangements in DNA topoisomerase II inhibitor-related leukemia in children. Blood 85:3250-3256, 1995
6. Pedersen-Bjergaard J, Pedersen M, Roulston D, et al: Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood 86:3542-3552, 1995
7. Cimino G, Rapanotti MC, Biondi A, et al: Infant acute leukemias show the same biased distribution of ALLI gene breaks as topoisomerase II related secondary acute leukemias. Cancer Res 57:2879-2883, 1997
8. LeBeau MM, Albain KS, Larson RA, et al: Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: Further evidence for characteristic abnormalities of chromosomes. J Clin Oncol 4:325-345, 1986
9. Kantarjian HM, Keating MJ, Walters RS, et al: Therapy-related leukemia and myelodysplastic syndrome: Clinical, cytogenetic, and prognostic features. J Clin Oncol 4:1748-1757, 1986
10. Levine EG, Bloomfield C: Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Semin Oncol 19:47-84, 1992
11. Pui C-H, Ribeiro RC, Hancock ML, et al: Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 325:1682-1687, 1991
12. Rubin CM, Arthur DC, Woods WG, et al: Therapy-related myelodysplastic syndrome and acute myeloid leukemia in children: Correlation between chromosomal abnormalities and prior therapy. Blood 78:2982-2988, 1991
13. Sandoval C, Pui CH, Bowman LC, et al: Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irradiation. J Clin Oncol 11:1039-1045, 1993
14. Tucker MA, Meadows AT, Boice JD, et al: Leukemia after therapy with alkylating agents for childhood cancer. J Natl Cancer Inst 78:459-464, 1987
15. Pui CH, Hancock ML, Raimondi SC, et al: Myeloid neoplasia in children treated for solid tumours. Lancet 336:417-421, 1990
16. Hawkins MM, Kinnier Wilson LM, Stovall MA, et al: Epipodophyllotoxins, alkylating agents, and radiation and risk of secondary leukaemia after childhood cancer. Br Med J 304:951-958, 1992
17. Olsen JH, Garwicz S, Hertz H, et al: Second malignant neoplasms after cancer in childhood or adolescence. Br Med J 307:1030-1036, 1993
18. Green DM, Zevon MA, Reese PA, et al: Second malignant tumors following treatment during childhood and adolescence for cancer. Med Pediatr Oncol 22:1-10, 1994
19. Heyn R, Khan F, Ensign LG, et al: Acute myeloid leukemia in patients treated for rhabdomyosarcoma with cyclophosphamide and low-dose etoposide on Intergroup Rhabdomyosarcoma Study III: An interim report. Med Pediatr Oncol 23:99-106, 1994
20. Breslow NE, Takashima JR, Whitton JA, et al: Second malignant neoplasms following treatment for Wilms' tumor: A report from the National Wilms' Tumor Study Group. J Clin Oncol 13:1851-1859, 1995
21. Kuttesch JF Jr, Wexler LH, Marcus RB, et al: Second malignancies after Ewing's sarcoma: Radiation dose-dependency of secondary sarcomas. J Clin Oncol 14:2818-2825, 1996
22. Pratt CB, Meyer WH, Luo X, et al: Second malignant neoplasms occurring in survivors of osteosarcoma. Cancer 80:960-965, 1997
23. Meresse V, Vassal G, Michon J, et al: Combined continuous infusion etoposide with high-dose cyclophosphamide for refractory neuroblastoma: A phase II study from the Societe Francaise d'Oncologie Pediatrique. J Clin Oncol 11:630-637, 1993
24. Zoubek A, Holzinger B, Mann G, et al: High-dose cyclophosphamide, Adriamycin, and vincristine (HD-CAV) in children with recurrent solid tumor. Pediatr Hematol Oncol 11:613-623, 1994
25. Carpenter PA, White L, McCowage GB, et al: A dose-intensive, cyclophosphamide-based regimen for the treatment of recurrent/ progressive or advanced solid tumors of childhood. A report from the Australia and New Zealand Children's Cancer Study Group. Cancer 80:489-496, 1997
26. Miser J, Krailo M, Smith M, et al: Secondary leukemia (SL) or myelodysplastic syndrome (MDS) following therapy for Ewing's sarcoma (ES). Proc Am Soc Clin Oncol 16:518a, 1997 (abstr)
27. Marina N, Pappo A, Parham D, et al: Intensified chemotherapy for pediatric Ewing's sarcoma (ES) or peripheral neuroepithelioma (PN). Proc Am Soc Clin Oncol 16:526a, 1997 (abstr)
28. Matthey KK: Neuroblastoma: Biology and therapy. Oncology 11:1857-1866, 1997
29. Cheung N-KV, Heller G: Chemotherapy dose-intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma. J Clin Oncol 9:1050-1058, 1991
30. Kushner BH, Helson L: Coordinated use of sequentially escalated cyclophosphamide and cell-cycle-specific chemotherapy (N4SE protocol) for advanced neuroblastoma: Experience with 100 patients. J Clin Oncol 5:1746-1751, 1987
31. Kushner BH, O'Reilly RJ, LaQuaglia M, et al: Dose-intensive use of cyclophosphamide in ablation of neuroblastoma. Cancer 66:1095-1100, 1990
32. Kushner BH, LaQuaglia MP, Bonilla MA, et al: Highly effective induction therapy for stage IV neuroblastoma in children over 1 year of age. J Clin Oncol 12:2607-2613, 1994
33. Cheung NK, Kushner B, LaQuaglia M, et al: N7: Combination chemotherapy, radio-immunotherapy and adjuvant antibody therapy for high-risk neuroblastoma (NB). Proc Am Soc Clin Oncol 17:438a, 1998 (abstr)
34. Kushner BH, Cheung N-KV, LaQuaglia MP, et al: Survival from locally invasive or widespread neuroblastoma without cytotoxic therapy. J Clin Oncol 14:373-381, 1996
35. Kushner BH, Cheung N-KV, LaQuaglia MP, et al: International Neuroblastoma Staging System stage I neuroblastoma: A prospective study and literature review. J Clin Oncol 14:2174-2180, 1996
36. Kushner BH, Gulati SC, Kwon JH, et al: High-dose melphalan with 6-hydroxydopamine-purged autologous bone marrow transplantation for poor-risk neuroblastoma. Cancer 68:242-247, 1991
37. Kushner BH, O'Reilly RJ, Mandell LR, et al: Myeloablative combination chemotherapy without total-body irradiation for neuroblastoma. J Clin Oncol 9:274-279, 1991
38. Saarinen UM, Coccia PF, Gerson SL, et al: Eradication of neuroblastoma cells in vitro by monoclonal antibody and human complement: Method for purging autologous bone marrow. Cancer Res 45:5969-5975, 1985
39. Bennett JM, Catovsky D, Daniel MT, et al: Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 103:620-625, 1985
40. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure Time Data. New York, NY, Wiley, 1980
41. Miller BA, Ries LAG, Hankey BF, et al (eds): SEER Cancer Statistics Review 1973-1990 National Cancer Institute. Bethesda, MD, National Institutes of Health publication no. 93-2789, 1993
42. Hero B, Niemeyer C, Dorffel W, et al: Increased incidence of second leukemia after maintenance chemotherapy in neuroblastoma patients. Med Pediatr Oncol 27:303, 1996 (abstr)
43. Tsunematsu Y, Watanabe S, Inoue R, et al: Multiple primary malignancies in childhood cancer. Jpn J Clin Oncol 15:223-233 1985
44. Mike V, Meadows AT, D'Angio GJ: Incidence of second malignant neoplasms in children: Results of an international study. Lancet 2:1326-1331, 1982
45. Meadows AT, Baum E, Fossati-Bellani F, et al: Second malignant neoplasms in children: An update from the Late Effects Study Group. J Clin Oncol 3:532-538, 1985
46. Grosfeld JL, Baehner RL: Neuroblastoma: An analysis of 160 cases. World J Surg 4:29-38, 1980
47. Coldman AJ, Fryer CJH, Elwood JM, et al: Neuroblastoma: Influence of age at diagnosis, stage, tumor site, and sex on prognosis. Cancer 46:1896-1901, 1980
48. Thomas PRM, Lee JY, Fineberg BB, et al: An analysis of neuroblastoma at a single institution. Cancer 53:2079-2082, 1984
49. Rosen EM, Cassady JR, Frantz CN, et al: Improved survival in neuroblastoma using multimodality therapy. Radiother Oncol 2:189-200, 1984
50. de Vathaire F, Schweisguth O, Rodary C, et al: Long-term risk of second malignant neoplasm after a cancer in childhood. Br J Cancer 59:448-452, 1989
51. Blatt J, Olshan A, Gula MJ, et al: Second malignancies in very-long-term survivors of childhood cancer. Am J Med 93:57-60, 1992
52. Smith MB, Xue H, Strong L, et al: Forty-year experience with second malignancies after treatment of childhood cancer: Analysis of outcome following the development of the second malignancy. J Pediatr Surg 28:1342-1349, 1993
53. Saito T, Tsunematsu Y, Saeki M, et al: Trends of survival in neuroblastoma and independent risk factors for survival at a single institution. Med Pediatr Oncol 29:197-205, 1997
54. Hayes FA, Green A, Hustu HO, et al: Surgicopathologic staging of neuroblastoma: Prognostic significance of regional lymph node metastases. J Pediatr 102:59-62, 1983
55. Evans A, Brand W, deLorimier A, et al: Results in children with local and regional neuroblastoma managed with and without vincristine, cyclophosphamide, and imidazolecarboxamide. Am J Clin Oncol 6:3-8, 1984
56. Nitschke R, Smith EI, Shochat S, et al: Localized neuroblastoma treated by surgery: A Pediatric Oncology Group study. J Clin Oncol 6:1271-1279, 1988
57. Matthay KK, Sather HN, Seeger RC, et al: Excellent outcome of stage II neuroblastoma is independent of residual disease and radiation therapy. J Clin Oncol 7:236-244, 1989
58. Garaventa A, De Bernardi B, Pianca C, et al: Localized but unresectable neuroblastoma: Treatment and outcome of 145 cases. J Clin Oncol 11:1770-1779, 1993
59. De Bernardi B, Conti M, Mancini A, et al: Localized resectable neuroblastoma: Results of the second study of the Italian Cooperative Group for Neuroblastoma. J Clin Oncol 13:884-893, 1995
60. Rubie H, Hartmann O, Michon J, et al: N-myc gene amplification is a major prognostic factor in localized neuroblastoma: Results of the French NBL90 study. J Clin Oncol 15:1171-1182, 1997
61. Evans AE, D'Angio GJ, Koop CE: The role of multimodal therapy in patients with local and regional neuroblastoma. J Pediatr Surg 19:77-80, 1984
62. Nickerson HJ, Nesbit ME, Grosfeld JL, et al: Comparison of stage IV and IV-S neuroblastoma in the first year of life. Med Pediatr Oncol 13:261-268, 1985
63. Suarez A, Hartmann O, Vassal G, et al: Treatment of stage IV-S neuroblastoma: A study of 34 cases treated between 1982 and 1987. Med Pediatr Oncol 19:473-477, 1991
64. Martinez DA, King DR, Ginn-Pease ME, et al: Resection of the primary tumor is appropriate for children with stage IV-S neuroblastoma: An analysis of 37 patients. J Pediatr Surg 27:1016-1021, 1992
65. De Bernardi B, Pianca C, Boni L, et al: Disseminated neuroblastoma (stage IV and IV-S) in the first year of life. Cancer 70:1625-1633, 1992
66. Guglielmi M, De Bernardi B, Rizzo A, et al: Resection of primary tumor at diagnosis in stage IV-S neuroblastoma: Does it affect the clinical course? J Clin Oncol 14:1537-1544, 1996
67. van Noesel MM, Hahlen K, Hakvoort-Cammel FGAJM, et al: Neuroblastoma 4S. A heterogeneous disease with variable risk factors and treatment strategies. Cancer 80:834-843, 1997
68. Berthold F, Brandeis WE, Lampert F: Neuroblastoma: Diagnostic advances and therapeutic results in 370 patients. Monogr Paediat 18:206-223, 1986
69. Sawaguchi S, Kaneko M, Uchino J, et al: Treatment of advanced neuroblastoma with emphasis on intensive induction chemotherapy. Cancer 66:1879-1887, 1990
70. De Bernardi B, Carli M, Casale F, et al: Standard-dose and high-dose peptichemio and cisplatin in children with disseminated poor-risk neuroblastoma: Two studies by the Italian Cooperative Group for Neuroblastoma. J Clin Oncol 10:1870-1878, 1992
71. McWilliams NV, Hayes FA, Green AA, et al: Cyclophosphamide/ doxorubicin vs cisplatin/ teniposide in the treatment of children older than 12 months of age with disseminated neuroblastoma: A Pediatric Oncology Group randomized phase II study. Med Pediatr Oncol 24:176-180, 1995
72. Coze C, Hartmann O, Michon J, et al: NB87 induction protocol for stage IV neuroblastoma in children over 1 year of age: A report from the French Society of Pediatric Oncology. J Clin Oncol 15:3433-3440, 1997
73. Pole JG, Casper J, Elfenbein G, et al: High-dose chemoradiotherapy supported by marrow infusions for advanced neuroblastoma: A Pediatric Oncology Group study. J Clin Oncol 9:152-158, 1991
74. Philip T, Zucker JM, Bernard JL, et al: Improved survival at 2 and 5 years in the LMCE1 unselected group of 72 children with stage IV neuroblastoma older than 1 year of age at diagnosis: Is cure possible in a small subgroup? J Clin Oncol 9:1037-1044, 1991
75. Philip T, Ladenstein R, Zucker JM, et al: Double megatherapy and autologous bone marrow transplantation for advanced neuroblastoma: The LMCE2 study. BrJ Cancer 67:119-127, 1993
76. Ladenstein R, Lasset C, Hartmann O, et al: Impact of megatherapy on survival after relapse from stage IV neuroblastoma in patients over 1 year of age at diagnosis: A report from the European Group for Bone Marrow Transplantation. J Clin Oncol 11:2330-2341, 1993
77. Ladenstein R, Lasset C, Hartmann O, et al: Comparison of auto versus allografting as consolidation of primary treatments in advanced neuroblastoma over one year of age at diagnosis: Report from the European Group for Bone Marrow Transplantation. Bone Marrow Transplant 14:37-46, 1994
78. Evans AE, August CS, Kamani N, et al: Bone marrow transplantation for high-risk neuroblastoma at the Children's Hospital of Philadelphia: An update. Med Pediatr Oncol 23:323-327, 1994
79. Ohnuma N, Takahashi H, Kaneko M, et al: Treatment combined with bone marrow transplantation for advanced neuroblastoma: An analysis of patients who were pretreated intensively with the protocol of the Study Group of Japan. Med Pediatr Oncol 24:181-187, 1995
80. Kamani N, August CS, Bunin N, et al: A study of thiotepa, etoposide and fractionated total body irradiation as a preparative regimen prior to bone marrow transplantation for poor prognosis patients with neuroblastoma. Bone Marrow Transplant 17:911-916, 1996
81. Garaventa A, Rondelli R, Lanino E, et al: Double megatherapy and autologous bone marrow transplantation for advanced neuroblastoma: The LMCE2 study. Bone Marrow Transplant 18:125-130, 1996
82. Stram DO, Matthay KK, O'Leary M, et al: Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: A report of two concurrent Children's Cancer Group studies. J Clin Oncol 14:2417-2426, 1996
83. Kletzel M, Abella EM, Sandier ES, et al : Thiotepa and cyclophosphamide with stem cell rescue for consolidation therapy for children with high-risk neuroblastoma: A phase I/II study of the Pediatric Blood and Marrow Transplant Consortium. J Pediatr Hematol/Oncol 20:49-54, 1998
84. Greenfield LJ, Shelley WM: The spectrum of neurogenic tumors of the sympathetic nervous system: Maturation and adrenergic function. J Natl Cancer Inst 35:215-226, 1965
85. Shah NR, Miller DR, Steinherz PG, et al: Acute monoblastic leukemia as a second malignant neoplasm in metastatic neuroblastoma. Am J Pediatr Hematol Oncol 5:309-314, 1983
86. Hartmann O, Oberlin O, Lemerle J, et al: Acute leukemia in two patients treated with high-dose melphalan and autologous marrow transplantation for malignant solid tumors. J Clin Oncol 2:1424-1425, 1984
87. Hunger SP, Sklar J, Link MP: Acute lymphoblastic leukemia occurring as a second malignant neoplasm in childhood: Report of three cases and review of the literature. J Clin Oncol 10:156-163, 1992
88. Seeker-Walker LM, Stewart EL, Todd A: Acute lymphoblastic leukaemia with t(4;11) follows neuroblastoma: A late effect of treatment? Med Pediatr Oncol 13:48-50, 1985
89. Weh HJ, Kabisch H, Landbeck G, et al: Translocation (9:11)(p21; q23) in a child with acute monoblastic leukemia following 21/2 years after successful chemotherapy for neuroblastoma. J Clin Oncol 4:1518-1520, 1986
90. Whang-Peng J, Young RC, Lee EC, et al: Cytogenetic studies in patients with secondary leukemia/dysmyelopoietic syndrome after different treatment modalities. Blood 71:403-414, 1988
91. Longmore G, Guinan EC, Weinstein HJ, et al: Bone marrow transplantation for myelodysplasia and secondary acute nonlymphoblastic leukemia. J Clin Oncol 8:1707-1714, 1990
92. Bowman LC, Hancock ML, Santana VM, et al: Impact of intensified therapy on clinical outcome of infants and children with neuroblastoma: The St Jude Children's Research Hospital experience, 1962 to 1988, J Clin Oncol 9:1599-1608, 1991
93. Pratt CB, Pui C-H: Secondary acute lymphoblastic leukemia in childhood (letter). J Clin Oncol 10:866, 1992
94. Sandoval C, Head DR, Mirro J Jr, et al: Translocation t(9; 11)(p21; q23) in pediatric de novo and secondary acute myeloblastic leukemia. Leukemia 6:513-519, 1992
95. Farhi DC, Odell CA, Shurin SB: Myelodysplastic syndrome and acute myeloid leukemia after treatment for solid tumors of childhood. Am J Clin Pathol 100:270-275, 1993
96. Imashuku S, Hibi S, Kosaka K, et al: Secondary lymphoid malignancy in two children with neuroblastoma. Med Pediatr Oncol 27:54-56, 1996
97. Felice MS, Zubizarreta PA, Chantada GL, et al: Acute myeloid leukemia as a second malignancy: Report of 9 pediatric patients in a single institution in Argentina. Med Pediatr Oncol 30:160-164, 1998
98. 131metaiodobenzylguanidine followed by autologous bone marrow transplantation for treatment of refractory neuroblastoma. Med Pediatr Oncol 30:339-346, 1998
99. Kushner BH, Heller G, Cheung NKV, et al: High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors. J Clin Oncol 16:3016-3020, 1998
100. Greene MH: Is cisplatin a human carcinogen? J Natl Cancer Inst 84:306-312, 1992
101. Bokemeyer C, Schmoll H-J: Treatment of testicular cancer and the development of secondary malignancies. J Clin Oncol 13:283-292, 1995
102. Karp JE, Smith MA: Modifying risks of secondary leukemias: Is drug scheduling important? J Natl Cancer Inst 88:1787-1789, 1996
103. Pui C-H, Boyett JM, Hughes WT, et al: Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med 336:1781-1787, 1997
104. Naparstek E: Granulocyte colony-stimulating factor, congenital neutropenia, and acute myeloid leukemia. N Engl J Med 333:516-518, 1995
105. Cheung IY, Cheung N-KV: Molecular detection of GAGE expression in peripheral blood and bone marrow: Utility as a tumor marker for neuroblastoma. Cancer Clin Res 3:821-826, 1997